Intracavitary ultrasound impairs left ventricular performance: presumed role of endocardial endothelium.

Irradiation of isolated cardiac muscle by high-power, high-frequency, continuous wave ultrasound selectively damages endocardial endothelium (EE). We evaluated this ultrasound effect in vivo on the performance of the intact ejecting canine left ventricle (LV). A cylindrical ultrasound probe (0.

Infrarenal aortic occlusion in the rabbit to assess the effect of flunarizine in the prevention of ischemic spinal cord injury.

Infrarenal aortic occlusion in rabbits to produce paraplegia is possible in large series and can be achieved without any side-effects of anesthetic drugs. This model was tested for its suitability to investigate the use of calcium-channel blockers, which potentially reduce or prevent ischemic spinal cord damage. In a pilot study 26 rabbits were treated with 0.

Effects of ketanserin, a 5-HT2-receptor antagonist, on the blood flow response to temperature changes in the diabetic foot.

We studied the effect of ketanserin, a relatively specific antagonist for 5-hydroxytryptamine2-serotonergic receptors, on the total blood flow to the foot of patients with diabetes using a computerized pulse volume plethysmograph and a temperature controlled foot chamber. Ketanserin was administered intravenously as a bolus of 10 mg over four minutes followed by a constant infusion at the rate of 5 mg/hr. Saline infusion served as a control in each subject.

Inhibition of cold-induced vasoconstriction with ketanserin.

The role of serotonin, thromboxane A2, and prostacyclin in cold-stimulated vasoconstriction was studied in 11 volunteers randomly pretreated with placebo, antagonists to serotonin (ketanserin, 40 mg), cyclooxygenase (ibuprofen, 800 mg), or thromboxane synthetase (ketoconazole, 400 mg). With an ambient temperature of 27 degrees, the hand and distal arm of one side were immersed in iced slush for 2 min. At the end of this time there was a fall in skin temperature from 31.

Treatment of Raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor.

Ketanserin, a selective antagonist of the 5-HT2 receptor, was evaluated in a 4-week open pilot trial of 30 patients with Raynaud's phenomenon. Moderate or marked relief was reported in 15 of 18 (83%) patients with systemic sclerosis, whereas only 4 of 12 (33%) patients with Raynaud's phenomenon of other etiology received such benefit (P less than 0.01).